Claret Capital Partners
VC Fund
London, United Kingdom
Claret Capital Partners is a VC fund in London focused on Software and Information Technology. Claret Capital provides specialty debt financing to European growth businesses, predominantly in the technology, life sciences and environmental sectors. Typical loan sizes range from €1M-€40M with the flexibility to do larger transactions opportunistically.They look for investment opportunities in high growth business with proven managementteams in need of capital to fuel organic growth, acquisitions, equipment purchases, bridge loans and various forms of recapitalization.
- Total investments:
- 118
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $410M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Claret Capital Partners invests in
Stages Claret Capital Partners invests in
Countries Claret Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Post-IPO Debt
- $5.5M–$165M
- Debt Financing
- $1.9M–$29M
- Venture - Series Unknown
- $1.6M–$95M
Investment Focus
Industry
- Software 32 (27%)
- Information Technology 16 (14%)
- Mobile 13 (11%)
- E-Commerce 13 (11%)
- Artificial Intelligence 13 (11%)
Stage
- Debt Financing 78 (66%)
- Venture - Series Unknown 11 (9%)
- Post-IPO Debt 7 (6%)
- Funding Round 4 (3%)
- Series A 3 (3%)
Country
- United Kingdom 27 (23%)
- Germany 22 (19%)
- United States 17 (14%)
- Ireland 11 (9%)
- France 10 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bryan McLoughlin
Vice President
|
Vice President | Total investments: 0 | Find email | |
David Bateman
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
Fahad Khan
Vice President
|
Vice President | Total investments: 0 | Find email | |
Jerome Fonteneau
Portfolio and Operations Director
|
Portfolio and Operations Director | Total investments: 0 | Find email | |
Johan Kampe
Senior Managing Director
|
Senior Managing Director | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Open Cosmos is a space technology company that designs, builds, and operates satellites to simplify access to space. The company also delivers end-to-end telecommunications, Earth Observation (EO), navigation, and scientific missions. It designs, builds, launches and operates advanced satellites through its OpenOrbit offering, that enablesorganizations to access and share data via its mutualized OpenConstellation infrastructure and offers AI-powered data analysis from a growing range of satellite sources and analytic partners through its DataCosmos platform. | $348M / Series C / Sep 14, 2026 | ||
| Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $29.1M / Debt Financing / Sep 09, 2026 | ||
| Affluent Medical develops innovative new-generation mini-invasive implants to restore essential physiological functions in these areas: - Kardiozis aims to prevent endoleaks and risks of recurrence of the abdominal aortic aneurysm allowing patients to live more serenely facing an unpredictable risk of breakage; - Kalios and Epygon aim to providemore physiological surgical treatments for the repair or replacement of the mitral valve of the heart. Kalios can treat residual post-operative leakage and recurrent mitral insufficiency without having to reoperate patients. Epygon is today the only developing transcatheter valve to restore natural blood flow and safeguard the left ventricle. - Finally, Artus is the first electronically activatable artificial sphincter to treat stress urinary incontinence in men and women. | $11.5M / Post-IPO Debt / Aug 06, 2026 | ||
| Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $151.5M / Post-IPO Debt / Jun 01, 2026 | ||
| PaySend is a financial technology platform that solves the universal problem to securely enable any bank card (Visa or MasterCard) to send and receive money worldwide. It is a next-generation money transfer platform allowing its users to send funds from card to card from 40 to over 60 countries. | $25M / Venture - Series Unknown / Mar 31, 2026 | ||
| Wellster is the go-to solution for everyday consumer health. It builds digital clinics along the lifecycle of next gen. health consumers. | $11.5M / Debt Financing / Mar 23, 2026 | ||
| Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $9.2M / Post-IPO Debt / Mar 13, 2026 | ||
| Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $17.6M / Debt Financing / Oct 02, 2025 | ||
| Most people suffer at some point during the life of mental illness. Whether it comes to periods of stress, drowsiness or worry that does not disappear by itself, a professional contact can be an effective way back and prevent negative development. They started Mindler with the vision that everyone should have the opportunity to meet a psychologiston equal terms, no matter where you live or what conditions you have. Digital technology and leading psychological skills are our model for increasing access to effective treatment of mental health and for people in our country to get the best help they need. | $11.6M / Debt Financing / Aug 27, 2025 | ||
| VIOTAS is an electric utility company that provides electric power and smart grid technology for commercial or industrial facilities. | $11.3M / Debt Financing / May 22, 2025 | ||
| See all 118 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Claret Capital Partners invest in?
Claret Capital Partners invests primarily in Software, Information Technology and Mobile startups, most often at Debt Financing and Venture - Series Unknown stage. Most of the 118 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Claret Capital Partners's check size?
Claret Capital Partners typically joins rounds of $5.5M–$165M at Post-IPO Debt, $1.9M–$29M at Debt Financing and $1.6M–$95M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Claret Capital Partners participates in.
How do I contact Claret Capital Partners?
Public channels for Claret Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Claret Capital Partners?
The team at Claret Capital Partners includes Bryan McLoughlin (Vice President), David Bateman (Managing Partner) and Fahad Khan (Vice President), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
